Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals has closed its previously announced registered direct equity offering of common stock and warrants. The company received net proceeds of approximately $3.5 million.
Subscribe to our email newsletter
Theodore Zucconi, president of Pro-Pharmaceuticals, said: “This financing, together with the ‘friends and family’ private placement we recently completed, enables us to reach critical milestones for Davanat and our fibrosis compounds.”